Kimberly Stegmaier named as Pediatric Oncology Chair at Dana-Farber
She will also serve as Associate Chief of Division of Hematology/Oncology at Boston Children’s Hospital
2025-02-19
(Press-News.org)
Boston - Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, in an announcement made today. Her appointment is effective April 1, 2025.
Stegmaier, a Dana-Farber, Boston Children’s Hospital, and Harvard Medical School faculty member since 2002, Stegmaier is currently Vice Chair for Pediatric Oncology Research at Dana-Farber, Co-Director of the Pediatric Hematologic Malignancy Program at Dana-Farber and Boston Children’s Hospital, Co-Leader for the Dana-Farber/Harvard Cancer Center Leukemia Program, and a Professor of Pediatrics at Harvard Medical School. She holds the Ted Williams Chair at Dana-Farber and is an Institute Member of the Cancer Program at the Broad Institute of Harvard & MIT.
“I am proud to know and to have worked alongside Kim Stegmaier for many years. She is deeply devoted to our young patients and their families, and to find new therapies. I am excited for her to lead our Department of Pediatric Oncology and build on its strong foundation for years to come,” said Benjamin L. Ebert, MD, PhD, president and CEO, Dana-Farber Cancer Institute.
As Chair of Pediatric Oncology, Stegmaier will be responsible for the full scope of clinical, research and educational activities of the department. She will work closely with David Williams, MD, Chief of the division of Hematology/Oncology at Boston Children’s Hospital to lead the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
A highly skilled physician-scientist, Kim is dedicated to the goal of precision pediatric oncology medicine, pioneering the development and application of innovative genomic approaches to identify new therapies for childhood cancer. She has focused her efforts on acute leukemias and pediatric solid tumors of childhood, particularly those driven by fusion oncoproteins. Her lab has discovered novel technologies, concepts, and targets with translational impact
Stegmaier is a principal investigator and renowned scientist who has been recognized by a range of national and international organizations, including the National Cancer Institute where she twice earned the NCI Outstanding Investigator Award and the Society for Pediatric Research where she received the E. Mead Johnson Award. A dedicated mentor, she was also the recipient of the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. Kim is an elected member of the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI), as well as a Board Member of the American Association for Cancer Research (AACR).
She has a BS from Duke University and an MD from Harvard Medical School. She completed her residency at Boston Children’s and a pediatric hematology-oncology fellowship at Dana-Farber/Boston Children’s.
Stegmaier’s appointment to this new role follows a nationwide search to succeed Scott Armstrong, MD, PhD, who was recent appointed to Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-02-19
NEW YORK – The Human Immunome Project (HIP) and Michelson Medical Research Foundation (MMRF) have awarded Dr. Omar Abudayyeh (Brigham and Women’s Hospital; Harvard Medical School), Dr. Caleb Lareau (Memorial Sloan Kettering Cancer Center), and Dr. Yuzhong Liu (Scripps Research) the 2024 Michelson Prizes: Next Generation Grants.
The $150,000 research grants are awarded annually to support early-career scientists advancing human immunology, vaccine discovery, and immunotherapy research for major global diseases.
“Investing in bold, early-career scientists fuels the high-risk, high-reward ideas ...
2025-02-19
After a year of weather extremes that brought everything from deadly floods to bitter cold, experts at East Tennessee State University have released a detailed analysis of the region’s 2024 weather patterns.
Their findings highlight both record-breaking temperatures and catastrophic storms – underscoring the growing need for preparedness as communities face unpredictable conditions.
The report, published by Tennessee’s Climate Office housed at ETSU, details how Southern Appalachia endured scorching heat and devastating floods, including the tragic September storm linked to ...
2025-02-19
Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren’t just aesthetically pleasing. They also play a crucial role in plant reproduction. In all plants, a well-studied gene with a curious name, Unusual Floral Organs (UFO), orchestrates the flowering process. UFO expression hinges on another complex process called cis-regulation. And this one has remained a “black box” of plant biology research for years.
Now, using CRISPR gene editing, Cold ...
2025-02-19
PHILADELPHIA – Cancer patients spend a lot of time on their care. Meeting with doctors and other members of their health care team, getting labs and other tests, picking up prescriptions, and undergoing treatment all takes time. So does getting to and from each appointment, sitting in the waiting room between each appointment, and so on.
In recent years, cancer researchers have worked to quantify the level of “time toxicity” or time spent commuting to, waiting for, and receiving cancer treatment. Now, for the first time, a pilot study has shown it’s possible to use digital technology to safely ...
2025-02-19
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal. Approximately, 1.5 million people are living with HIV in Uganda.
“Our data shows that only 1.6% of the individuals studied are living with HIV ...
2025-02-19
There are currently around 275,000 glaciers worldwide, in which huge quantities of fresh water are stored. But this reservoir is increasingly shrinking. Since the turn of the millennium, glaciers around the world – i.e. ice masses on land excluding the Greenland and Antarctic ice sheets – have lost around 273 billion tonnes of ice per year. This corresponds to about five and a half times the volume of Lake Constance. Overall, the world’s glaciers have lost around five per cent of their total volume since the year 2000. This is the conclusion reached by an international research team of which Tobias Bolch from the Institute of Geodesy ...
2025-02-19
February 19, 2025-- Breast cancer incidence trends in U.S. women under 40 vary by geography and supports incorporating location information with established risk factors into risk prediction, improving the ability to identify groups of younger women at higher risk for early-onset breast cancer, according to a new study at Columbia University Mailman School of Public Health. This study comprehensively examined trends across different states, regions, metropolitan versus non-metropolitan areas and by racial and ethnic groups. It also is one of the first to incorporate ...
2025-02-19
A three-year effort to encourage California prosecutors to reconsider the sentences given to some people in state prison has resulted in a modest number of people being resentenced, but improvements are needed to speed review of more cases, according to a new RAND report.
During the project involving nine counties, more than 1,100 cases received an initial review. After comprehensive reviews by county district attorneys for the suitability for resentencing, 227 individuals eventually received new sentences and 174 of those offenders had been released ...
2025-02-19
Propane dehydrogenation (PDH), as an efficient catalytic production process to obtain propylene, has developed rapidly in recent years. Previous studies have shown that zirconia exhibited excellent performance in the PDH, with the coordination-unsaturated zirconium (Zrcus) around the oxygen vacancy being the active site in the reaction. However, the critical role of oxygen vacancy is still remaining elusive, and lacked a rationale to establish a relation between structure and performance. Moreover, the strong binding of propene and hydrogen molecules shadowed ...
2025-02-19
CHAMPAIGN, Ill. — A genetic mutation found in two human patients with schizophrenia also increased schizophrenia-related behaviors in mice with the same mutation, a rare finding of a direct genetic link to psychosis, report researchers at the University of Illinois Urbana-Champaign and colleagues in Massachusetts and Germany.
The mutation increases levels of glycine decarboxylase, or GLDC, an enzyme responsible for regulating glycine in the brain. Glycine activates receptors for the neurotransmitter glutamate, called NDMA receptors.
“The genetics of schizophrenia is very complex, and it ...
LAST 30 PRESS RELEASES:
[Press-News.org] Kimberly Stegmaier named as Pediatric Oncology Chair at Dana-Farber
She will also serve as Associate Chief of Division of Hematology/Oncology at Boston Children’s Hospital
